Sage Therapeutics Q3 2016 Financial Results and CNS Drug Development

Sage Therapeutics presented Q3 2016 financial results and clinical updates on November 3, 2016, focusing on its novel CNS disorder therapies including SAGE-547. The presentation covered business highlights, clinical progress, financial performance, and forward-looking development milestones for the company's life-altering medicines portfolio.